Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Cost-effectiveness Analysis of Alemtuzumab in comparison with Natalizumab for relapsing-remitting multiple sclerosis treatment in Iran

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: TAHERI, Saeed (Shahid Beheshti University of Medical Science, Dept. of pharmacoeconomics and Pharma Management, Tehran, Iran, Islamic Republic Of)
  • Co-author(s): Saeed Taheri: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
    Nazila yousefi: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
    Mohammad Ali Sahraian: MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic Of
    Gholamhossein Mehralian: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
  • Abstract:

    Backgrounds

    In recent years, although new drugs lead to better outcomes, their increasing costs has become a challenging issue for governments and patients. So, economic evaluation of new expensive treatments has been increasingly applied to justify the balance between the additional costs of new drugs and their incremental benefits.

    Aims

    In this

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses